A company can launch a hostile takeover. If it is higher than Pfizer's bid the independent valuation will say to go with the higher bid. If they buy 19.9% on market, there is not much Pfizer or Rap's board can do about it.
Ann: Proposed Acquisition of ResApp Health by Pfizer, page-353
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #